Page 438 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(137) Choudhry NK, Stelfox HT, Detsky AS. Relationships between
authors of clinical practice guidelines and the pharmaceutical industry.
JAMA. 2002 Feb 6;287 (5):612–7.

(138) Galanter M, Galanter M, Felstiner WLF, Friedman LM, Girth
M, Goldstein P, et al. Why the haves come out ahead: Speculations on the
limits of legal change. Law Society Review. 1974;9:95–169.

‫ ﺑﻴﺎﻧﺎت أﻓﻀﻞ‬:‫ﺧﺎﺗﻤﺔ‬

(1) Department of Justice, Office of Public Affairs. GlaxoSmithKline to
Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to
Report Safety Data. Monday, July 2, 2012. http://www.justice.gov/opa/pr/
2012/July/12-civ-842.html.

(2) Glaxo executives cited in case now lead Sanofi, Actelion. Bloomberg
News, 3/7/12. http://www.businessweek.com/news/2012-07-03/glaxo-
executives-cited-in-case-now-lead-sanofi-actelion.

(3) Inpharm 4/7/12. GSK ruling: another failing, but will the indus-
try learn? http://www.inpharm.com/news/173307/gsk-ruling-another-
failing-will-industry-learn.

(4) Glaxo Agrees to Pay $3 Billion in Fraud Settlement. New York
Times, July 2 2012. http://www.nytimes.com/2012/07/03/business/
glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html.

(5) Level playing field push to continue despite setback – 8 Decem-
ber 2011. Medicines Australia. http://medicinesaustralia.com.au/2011/
12/08/level-playing-field-push-to-continue-despite-setback/.

(6) Drug companies to work with CCGs on care pathways
and case finding under DH-backed scheme. Pulse, 28 May 2012,
www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/
14029608/drug-companies-to-work-with-ccgs-on-care-pathways-
and-case-finding-under-dh-backed-scheme.

438